24-Week Results of a Blinded Phase 2b Dose-Ranging Study of Baricitinib, an Oral Janus Kinase 1/Januse Kinase 2 Inhibitor, in Combination with Traditional Disease Modifying Antirheumatic Drugs in Patients with Rheumatoid Arthritis.

24-Week Results of a Blinded Phase 2b Dose-Ranging Study of Baricitinib, an Oral Janus Kinase 1/Januse Kinase 2 Inhibitor, in Combination with Traditional Disease Modifying Antirheumatic Drugs in Patients with Rheumatoid Arthritis.

Bibliographic Details
Main Authors: Genovese, M, Keystone, E, Taylor, P, Drescher, E, Berclaz, P, Lee, C, Schlichting, D, Beattie, S, Fidelus-Gort, R, Luchi, M, Macias, W
Format: Conference item
Published: 2012

Similar Items